Get the app
USHealthcare

Odyssey Therapeutics, Inc. Common Stock (ODTX)

US · Healthcare · Biotechnology

$23.22+0.43%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-52.8M
EPS
$-1.26
EPS estimate
$-0.83

EPS came in at -1.26 against a street estimate of -0.83 — a miss of 51.8%.

Key statistics

Market cap
$1.14B
Forward P/E
0.0
P/B
2.78
Book value
$8.79
EPS (TTM)
$-3.24
52-week high
$29.05
52-week low
$15.10
50-day MA
$20.78
200-day MA
$19.43

Analyst view

with an average price target of $35.75.

Shareholding

Insiders
6.07%
Institutions
82.91%

Largest institutional holders

FundStake
SR ONE CAPITAL MANAGEMENT, LP7.90%
Lightspeed Management Co LLC7.51%
Sanofi4.14%
Sands Capital Ventures, LLC1.82%
Hillhouse Capital Advisors, Ltd.1.73%
General Catalyst Group Management, LLC1.69%
Adage Capital Partners Gp LLC1.51%
Foresite Capital Management V, LLC1.48%

Recent filings & reports

DocumentDate
Reg FD disclosure · Q3 2026
ODYSSEY THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • This is a Form 8-K filing dated September 8, 2026 — a current report disclosing material
2026-09-09
Quarterly report · Q2 2026
ODYSSEY THERAPEUTICS, INC. - 10-Q SUMMARY For Quarterly Period Ended June 30, 2026 --- HEADLINE NUMBERS • Cash and marketable securities combined:
2026-08-06
Results announced · Q3 2026
ODYSSEY THERAPEUTICS - Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash on hand as of June 30, 2026: $433.1 million (expected to fund opera
2026-08-04
Reg FD disclosure · Q2 2026
ODYSSEY THERAPEUTICS, INC. – 8-K FILING SUMMARY HEADLINE NUMBERS • Company: Odyssey Therapeutics, Inc. (ticker: ODTX, traded on Nasdaq) • Filing Dat
2026-06-23
Quarterly report · Q1 2026
ODYSSEY THERAPEUTICS, INC. — 10-Q SUMMARY (Q1 2026) HEADLINE NUMBERS • Cash position: $35.7 million in cash and cash equivalents as of March 31, 202
2026-06-17
Results announced · Q2 2026
ODYSSEY THERAPEUTICS Q1 2026 SUMMARY HEADLINE NUMBERS • Cash position: $175.7 million as of March 31, 2026 • Pro-forma cash (including IPO proceeds)
2026-06-17
Material agreement · Q2 2026
ODYSSEY THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Private placement of 1,388,889 common shares closed on May 7, 2026 • Share price: $18.00
2026-05-11

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Odyssey Therapeutics, Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.